Overview Cumulus Neuroscience published final CNS-102 results showing that its at-home NeuLogiq platform is feasible and well tolerated in people with ALS and FTD. The platform combines at-home EEG wi...
Conversations Shaping Tomorrow's Healthcare
Overview Cumulus Neuroscience published final CNS-102 results showing that its at-home NeuLogiq platform is feasible and well tolerated in people with ALS and FTD. The platform combines at-home EEG wi...